W
WAVEMAN · COMPANY
OTLC · Oncotelic Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

OTLC

Oncotelic Therapeutics, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0000908259
C-SUITE BUYING · 2☆ WATCH
INSIDER NET · 180D
$38.5K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
2
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
REVENUE GROWTH
-96.0%
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$38.5K over 180 days
+$38.5K over 90 days · +$37.5K of it by a 10%+ holder
more than 71% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
-96.0% year over year
below 92% of Pharma & Biotech
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
<0.1% of shares outstanding short · 1.0 days to cover · settled 2026-07-31
the lowest in Pharma & Biotech
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -30.0%
-30.0%12M
-40%+13%+67%+120%2025-092025-102025-122026-032026-052026-072026-09 2026-07-01 · Trieu Vuong bought $10.3K2026-06-17 · Trieu Vuong bought $9.6K2026-06-24 · Trieu Vuong bought $5.8K2026-06-15 · Trieu Vuong bought $4.8K2026-06-23 · Trieu Vuong bought $3.8K2026-06-22 · Trieu Vuong bought $3.2K2026-06-22 · Shah Amit B. bought $1.0K
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $38.5K bought by insiders over 180 days. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Oncotelic Therapeutics, Inc. insiders bought a net $38.5K of stock across 25 Form 4 purchases and sales, with 2 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Trieu Vuong
CHAIRMAN AND CEO
BUY
2026-07-01
240,000.0
$10.3K
Trieu Vuong
CHAIRMAN AND CEO
BUY
2026-06-24
115,000.0
$5.8K
Trieu Vuong
CHAIRMAN AND CEO
BUY
2026-06-23
75,000.0
$3.8K
Trieu Vuong
CHAIRMAN AND CEO
BUY
2026-06-22
65,000.0
$3.2K
Shah Amit B.
CFO
BUY
2026-06-22
20,000.0
$1.0K
25 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 20 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$70.0K
OPERATING INCOME$-3.2M$-3.6M$-6.6M$-9.7M
NET INCOME$249.3M$-4.5M$-7.9M$5.1M
EPS (DILUTED)0.59-0.01-0.020.01
OPERATING CASH FLOW$-1.4M$-740.3K$-1.3M$-1.5M
CASH$170.4K$241.5K
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →